CERO THERAPEUTICS HOLDINGS, INC. Shares Outstanding (Cover Page)
CERO THERAPEUTICS HOLDINGS, INC. (CERO) had Shares Outstanding (Cover Page) of 71.63 million shares as of 2026-08-13, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Cover Page
dei:EntityCommonStockSharesOutstanding · last filed 2026-08-14
- 2026-08-13: Entity Common Stock, Shares Outstanding 71.63M shares.
- 2026-05-14: Entity Common Stock, Shares Outstanding 45.11M shares.
- 2026-04-14: Entity Common Stock, Shares Outstanding 36.79M shares.
- 2025-11-19: Entity Common Stock, Shares Outstanding 21.10M shares.
| Period end | Entity Common Stock, Shares Outstanding |
|---|---|
| 2026-08-13 | 71.63M shares 10-Q · filed 2026-08-14 |
| 2026-05-14 | 45.11M shares 10-Q · filed 2026-05-15 |
| 2026-04-14 | 36.79M shares 10-K/A · filed 2026-04-30 |
| 2025-11-19 | 21.10M shares 10-Q · filed 2025-11-19 |
| 2025-08-21 | 1.21M shares 10-Q · filed 2025-08-22 |
| 2025-05-14 | 7.72M shares 10-Q · filed 2025-05-15 |
| 2025-04-24 | 5.58M shares 10-K/A · filed 2025-04-28 |
| 2025-04-11 | 5.38M shares 10-K · filed 2025-04-15 |
| 2024-11-19 | 150.31M shares 10-Q/A · filed 2024-11-20 |
| 2024-08-13 | 50.74M shares 10-Q · filed 2024-08-14 |
| 2024-05-10 | 15.06M shares 10-Q · filed 2024-05-17 |
| 2024-04-01 | 14.72M shares 10-K · filed 2024-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |